Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperidone Long-acting Microspheres in Schizophrenia Disorders
NCT01855074Phase 4Completed
- Sponsor
- Janssen-Cilag
- Start
- Nov 2007
- Primary completion
- Feb 2009
- Modality
- Small Molecules
01
Overview
Phase 4, open-label, single-arm trial of risperidone in schizophrenia, schizophreniform disorder and schizoaffective disorder, sponsored by Janssen-Cilag. Primary endpoint: Positive and Negative Syndrome Scale Total Score at Week 26. Started Nov 2007; status: completed.
02
Drugs
risperidone
03
Conditions
schizophreniaschizophreniform disorderschizoaffective disorder
Beyond the preview
Go deeper on NCT01855074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01855074.